Ventricular Sigmoid Septum as a Risk Factor for Anthracycline-Induced Cancer Therapeutics-Related Cardiac Dysfunction in Patients With Malignant Lymphoma-Reference-Cited by-同舟云学术

Ventricular Sigmoid Septum as a Risk Factor for Anthracycline-Induced Cancer Therapeutics-Related Cardiac Dysfunction in Patients With Malignant Lymphoma

Published:2022-04-08 Issue:4 Volume:4 Page:173-182
ISSN:2434-0790
Container-title:Circulation Reports
language:en
Short-container-title:Circ Rep

Author:

Nakayama Takafumi¹,Oshima Yoshiko²,Shintani Yasuhiro¹,Yamamoto Junki¹,Yokoi Masashi¹,Ito Tsuyoshi¹,Wakami Kazuaki¹,Kitada Shuichi¹,Goto Toshihiko¹,Hashimoto Hiroya³,Kusumoto Shigeru²,Sugiura Tomonori¹,Iida Shinsuke²,Seo Yoshihiro¹

Affiliation:

1. Department of Cardiology, Nagoya City University Graduate School of Medical Sciences

2. Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences

3. Clinical Research Management Center, Nagoya City University Hospital

Publisher

Japanese Circulation Society

Subject

Marketing,Organizational Behavior and Human Resource Management,Strategy and Management,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/circrep/4/4/4_CR-21-0145/_pdf

Reference46 articles.

1. 1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242.